Review demonstrates recent advances in CDK inhibitors for cancer, suggesting new treatment opportunities.
Key Points
This research examines cyclin-dependent kinases as therapeutic targets for cancer treatment. It aims to highlight recent advancements and challenges in CDK inhibitor therapies.
Review of literature on cyclin-dependent kinases in cancer.
Summarization of clinical outcomes related to CDK4/6 inhibitors.
Assessment of dual CDK4/6 and CDK2 inhibition effects.
Evaluation of CDK inhibitors in conjunction with cancer immunotherapy.
CDK4/6 inhibitors have shown clinical efficacy in HR+/HER2- metastatic breast cancer.
Selective CDK2 inhibitors have demonstrated promising antitumor activity.
Dual inhibition enhances effectiveness against CDK4/6 resistance.
CDK inhibitors can induce cellular senescence and improve immunotherapy outcomes.